Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Ovarian Neoplasms × exemestane × Clear all

Phase

Status

Terminated 1 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 21 Neoplasm Metastasis 3 Premenopausal Breast Cancer 1 Ovarian Neoplasms 1 Invasive Early Breast Cancer 1 First Line Metastatic Breast Cancer 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Neoplasms, Male 1 Breast Cancer Metastatic 1

Interventions

Carboplatin 39 Paclitaxel 37 liposomal doxorubicin 22 pembrolizumab 16 Topotecan 15 Cyclophosphamide 15 Bevacizumab 14 Gemcitabine 13 Cisplatin 12 niraparib 9 fludarabine 7 Docetaxel 7 aldesleukin 6 1-dodecylpyridoxal 6 olaparib 5 fludarabine phosphate 5 Nivolumab 5 oregovomab 4 durvalumab 4 avelumab 4 Surgical Procedures, Operative 4 Peripheral Blood Stem Cell Transplantation 4 Melphalan 4 Interleukin-2 4 Etoposide 4 Doxorubicin 4 spartalizumab 3 sargramostim 3 rucaparib 3 pegfilgrastim 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04460807 2024-02-12

EXPERT

Ente Ospedaliero Ospedali Galliera

Phase 3 Terminated

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡